NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Grocery Outlet Holding Corp. (NASDAQ:GO) on behalf of long-term stockholders following a class action complaint that was filed against Grocery Outlet on January 30, 2025 with a Class Period from August 9, 2023, to October 29, 2024. Our investigation concerns whether the board of directors of Grocery Outlet have breached their fiduciary dutie ...

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Elanco Animal Health Incorporated due to a class action complaint alleging breaches of fiduciary duties by the board of directors [1] Group 1: Allegations and Complaints - The class action complaint filed against Elanco alleges that during the Class Period, the company made materially false and misleading statements regarding its business and operations [2] - Specific allegations include that Zenrelia was less safe than represented, and that Elanco was unlikely to meet its timeline for U.S. approval and commercial launch of Zenrelia and Credelio Quattro [2] - The complaint asserts that these misrepresentations led to an overstatement of the company's business and financial prospects [2] Group 2: Contact Information - Long-term stockholders of Elanco are encouraged to contact Bragar Eagel & Squire, P.C. for more information regarding the claims and their rights [3] - The law firm provides contact details for inquiries, emphasizing that there is no cost or obligation for stockholders [3][6] Group 3: About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various complex litigations [4] - The firm operates in both New York and California, focusing on commercial and securities litigation [4]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Rocket Lab USA, Inc. due to a class action complaint alleging breaches of fiduciary duties by the board of directors during a specified class period [1] Group 1: Allegations and Delays - A report by Bleecker Street Research claims Rocket Lab misled investors regarding the launch timeline of its Neutron rocket, which is now delayed to a window starting September 2025 to March 2026 [2] - The report highlighted significant delays in preparing the launch pad, particularly a potable water issue that will not be resolved until January 2026, further postponing the launch [2] - The only contract for the Neutron rocket is with a startup described as unreliable, and the contract is not a full-price deal as previously stated by Rocket Lab [2] Group 2: Class Action Complaint Details - The class action complaint alleges that Rocket Lab made materially false or misleading statements and failed to disclose critical adverse facts about its business and operations [3] - Specific failures include not disclosing the delays in barge landing tests, the critical potable water issue, and the substantial risk of not launching the Neutron rocket in mid-2025 [3] - The complaint asserts that the positive statements made by the defendants regarding the company's prospects were materially misleading and lacked a reasonable basis [3]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Newmont Corporation due to a class action complaint alleging breaches of fiduciary duties by the board of directors [1][2] Summary by Relevant Sections Class Action Complaint - The complaint was filed on January 31, 2025, covering a Class Period from February 22, 2024, to October 23, 2024 [1] - Allegations include that defendants made false or misleading statements regarding Newmont's revenue outlook and production capabilities, creating a false impression of reliability [2] Investigation Details - The investigation focuses on whether the board of directors failed to fulfill their fiduciary responsibilities to the company [1] - The complaint claims that the defendants provided materially flawed statements of confidence and growth projections that did not consider critical variables [2]

Core Viewpoint - A class action lawsuit has been filed against Merck & Co., Inc. alleging that the company made false and misleading statements regarding its revenue outlook and growth prospects for Gardasil, particularly in relation to competition and drug approval developments [1][2]. Group 1: Allegations of Misleading Statements - The lawsuit claims that Merck created a false impression of having reliable information about its projected revenue and growth for Gardasil while downplaying competitive risks and drug approval challenges [2]. - It is alleged that Merck's optimistic reports regarding growth and demand in China were not reflective of the actual situation, indicating a material decline in the company's ability to drive demand for Gardasil [2]. Group 2: Impact on Stock Price - Following the announcement on July 30, 2024, regarding a significant drop in shipments from its distributor, Merck's stock price fell nearly 10% [3]. - On February 4, 2025, after disclosing a 3% decline in Gardasil sales to $8.6 billion, Merck's stock price dropped more than 9% [4]. Group 3: Legal Representation - Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of long-term stockholders of Merck and is encouraging individuals with information or questions to reach out [1][5].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Integral Ad Science Holding Corp. (IAS) on behalf of long-term stockholders following a class action complaint filed against IAS, alleging breaches of fiduciary duties by the board of directors [1][2] Summary by Relevant Sections Class Action Complaint - The complaint alleges that during the Class Period from March 2, 2023, to February 27, 2024, IAS misrepresented and failed to disclose significant competitive pricing pressures, leading to price cuts due to weakening demand and slowing revenue growth [2] - It is claimed that IAS's pricing function was no longer favorable, affecting its ability to sustain pricing and drive price increases, which became a key differentiator in closing major renewals and new deals [2] - The complaint states that the risk of increased pricing pressure from competition had materialized, resulting in materially false and misleading public statements from IAS [2] - As a result of these alleged wrongful acts, the market value of IAS shares declined significantly, causing losses for the plaintiff and potential class members [2] Law Firm Background - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California, representing individual and institutional investors in various complex litigations [3]